Serving as a field-based extension of the Company's Medical Affairs Department, the Medical Science Liaison (MSL) will represent the Company and its product approved to treat adults with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH).
The MSL will deliver clinical and scientific data to thought leaders, payers and other stakeholders within the cardiopulmonary community. The MSL is responsible for developing, coordinating and assuring implementation of corporate, scientific and clinical strategies to these thought leaders within various practice settings, including academic institutions, PH Care Centers and certain community based practices with a strong focus in PH clinical and health care organizations. The MSL will build long-term peer-to-peer relationships and establish rapport with these thought leaders through highly scientific product and disease-related discussions. These scientific exchanges will support and/or expand current cardiopulmonary therapeutic concepts, as well as ensure the safe and effective utilization of the Company's product(s).
Serving as the technical and scientific support in the field for healthcare providers, the MSL will ensure safe and effective use of the Company’s products through facilitation of timely adverse event reporting and provision of responses to unsolicited requests for detailed product and disease state information. The MSL will also serve as a conduit for unsolicited investigator initiated research ideas and will support company sponsored studies through investigator engagement.